Cadrenal Therapeutics

#Cardiovascular #Anticoagulation #Hematology

Late-stage biopharmaceutical company (NASDAQ: CVKD) developing tecarfarin, a novel oral reversible anticoagulant for patients with implanted cardiac devices, and CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia.

Company Info

Sector:Biopharmaceuticals — Cardiovascular

Headquarters:Ponte Vedra, Florida, USA

Founded:2022

Website:www.cadrenal.com/

Upcoming Milestones & Key Dates

2026-H2

corporate

Outcome of strategic review of cardiology pipeline

Clinical Development Pipeline

Tecarfarin

Target: Vitamin K epoxide reductase

Anticoagulation in patients with implanted cardiac devices

Preclinical

Phase 1

Phase 2

Phase 3

Approved

CAD-1005

Target: 12-LOX inhibitor

Heparin-induced thrombocytopenia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Quang X. Pham

Chairman and Chief Executive Officer

John P. Sharp

Interim Chief Financial Officer (since June 2026)

Careers & Job Openings

See all open roles

All departments

See company careers site

Apply Now →